Nutriband (NTRB) AI Stock Analysis

• Market Cap: $68.08M
• Dividend Yield: N/A
• Average Volume (3M): 35.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.68
• Revenue Growth: -3.18%
• EPS Growth: -5.80%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): -0.71
• Shares Outstanding: 11,106,185
• 10 Day Avg. Volume: 13,168
• 30 Day Avg. Volume: 35,919
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 49.92
• Price to Cash Flow (P/CF): -18.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $13.00
• Price Target Upside: 124.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Nutriband's stock shows potential through strategic corporate events, such as partnerships and patent expansions, which may drive future growth. However, financial sustainability remains a concern due to persistent losses and negative cash flows. Technical indicators suggest current positive momentum, but valuation metrics indicate caution.

Nutriband Business Overview & Revenue Model

Company Description

Nutriband Inc. is a healthcare company that operates primarily in the pharmaceutical and medical device sectors. The company focuses on the development and commercialization of advanced transdermal products, with a particular emphasis on transdermal drug delivery systems. These systems provide a method for delivering medications through the skin, offering an alternative to traditional oral administration methods.

How the Company Makes Money

Nutriband Inc. generates revenue through the development and sale of transdermal drug delivery systems. Their business model involves the research, development, and licensing of these systems to pharmaceutical companies. A significant portion of their revenue comes from partnerships and collaborations with other companies in the pharmaceutical industry, enabling them to leverage their technology for a variety of therapeutic applications. Additionally, Nutriband may earn income from royalties, licensing fees, and potential sales of their proprietary transdermal products, as well as through strategic partnerships that allow them to expand their market reach and product offerings.

Nutriband Financial Statement Overview

Summary

Nutriband's financial performance is challenged by negative net margins and cash flows, despite having a strong equity position and low leverage. Continued losses indicate sustainability concerns.

Income Statement

Nutriband's income statement reveals challenges in profitability, with negative net profit margins and declining EBIT margins over time. The company has been unable to achieve positive net income, indicating continued losses despite revenue growth, which is a concern for sustainability.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio, indicating financial stability. However, the recurring losses have impacted the return on equity negatively. The low debt-to-equity ratio suggests low leverage, which is positive for financial health.

Cash Flow

Cash flow analysis shows consistent negative free cash flow, reflecting operational challenges. The operating cash flow remains negative, indicating that the company is not generating enough cash from its core operations to cover expenses, leading to reliance on external financing.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
2.02M	2.09M	2.08M	1.42M	943.70K	370.65K
	Gross Profit
617.02K	862.11K	750.41K	504.31K	361.32K	-178.46K
	EBIT
-6.03M	-4.87M	-4.15M	-3.93M	-2.60M	-1.97M
	EBITDA
-6.52M	-5.12M	-4.11M	-5.74M	-2.48M	-2.56M
	Net Income Common Stockholders
-6.85M	-5.49M	-4.81M	-8.42M	-3.21M	-2.80M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
100.00	492.94K	1.99M	4.89M	151.99K	10.18K
	Total Assets
330.00	7.52M	9.46M	12.74M	9.93M	2.20M
	Total Debt
10.60K	241.28K	185.81K	134.57K	1.79M	321.62K
	Net Debt
10.50K	-251.66K	-1.80M	-4.76M	1.64M	311.44K
	Total Liabilities
11.80K	1.08M	883.39K	880.38K	2.82M	2.02M
	Stockholders Equity
-11.47K	6.44M	8.57M	11.86M	7.11M	175.43K
Cash Flow		Free Cash Flow
-4.25M	-3.58M	-3.07M	-2.89M	-297.06K	-894.47K
	Operating Cash Flow
-4.11M	-3.53M	-2.99M	-2.81M	-297.06K	-894.47K
	Investing Cash Flow
-141.18K	-51.76K	-79.30K	-81.59K	66.99K	0.00
	Financing Cash Flow
8.68M	2.09M	160.07K	7.63M	371.87K	430.25K

Nutriband Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTRB, the sentiment is Negative. The current price of 5.78 is below the 20-day moving average (MA) of 6.48, below the 50-day MA of 7.03, and below the 200-day MA of 5.86, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 36.12 is Neutral, neither overbought nor oversold. The STOCH value of 11.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NTRB.

Nutriband Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	78 Outperform	$12.05B	74.55	23.55%	―	39.94%	32.10%
PCRX	61 Neutral	$1.15B	―	-12.08%	―	3.85%	-339.15%
NTRB	59 Neutral	$68.08M	―	-80.83%	―	-3.18%	-5.80%
EBS	50 Neutral	$264.08M	―	-33.67%	―	-0.62%	75.57%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
TTNP	41 Neutral	$3.23M	―	-103.63%	―	-100.00%	28.48%

Nutriband Corporate Events

Nutriband Expands Partnership with Kindeva for Aversa™

Nutriband Inc. announced the signing of an addendum to its agreement with Kindeva Drug Delivery, formalizing their exclusive partnership and long-term commitment for the development of Aversa™ Fentanyl. This partnership aims to leverage Nutriband’s AVERSA™ abuse-deterrent technology to create the world’s first abuse-deterrent opioid patch, potentially reaching peak annual US sales of $80 million to $200 million.

Nutriband Secures USPTO Notice for Aversa™ Technology

On February 7, 2025, Nutriband Inc. announced it received a Notice of Allowance from the USPTO for its patent application covering the Aversa™ abuse deterrent technology. This development is anticipated to enhance Nutriband’s intellectual property protection in the U.S. for its transdermal systems designed to deter drug abuse and misuse. The AVERSA™ technology, protected by an extensive international patent portfolio, is aimed at preventing the abuse and accidental exposure of drugs, with the potential for significant market impact, particularly through its Aversa™ Fentanyl patch.

Nutriband Expands AVERSA™ Patent to Macao

Nutriband has extended its Chinese patent for the AVERSA™ abuse-deterrent transdermal technology to Macao, marking a significant expansion in its global intellectual property portfolio. This move supports the company’s strategic development of AVERSA™ Fentanyl, which could become the first abuse-deterrent opioid patch, potentially impacting market dynamics in opioid safety and accessibility.